Panel docking of small-molecule libraries - Prospects to improve efficiency of lead compound discovery.

[1]  Daniel Rauh,et al.  De Novo Design of Protein Kinase Inhibitors by in Silico Identification of Hinge Region-Binding Fragments , 2013, ACS chemical biology.

[2]  Dario R Alessi,et al.  Kinase drug discovery--what's next in the field? , 2013, ACS chemical biology.

[3]  R. Quinn,et al.  Guiding principles for natural product drug discovery. , 2012, Future medicinal chemistry.

[4]  M. Krasavin.  Novel diversely substituted 1-heteroaryl-2-imidazolines for fragment-based drug discovery , 2012 .

[5]  G. Bifulco,et al.  Inverse Virtual Screening allows the discovery of the biological activity of natural compounds. , 2012, Bioorganic & medicinal chemistry.

[6]  Andreas Hofmann,et al.  Similar interactions of natural products with biosynthetic enzymes and therapeutic targets could explain why nature produces such a large proportion of existing drugs. , 2011, Natural product reports.

[7]  Jun-Xu Li,et al.  Imidazoline I2 receptors: target for new analgesics? , 2011, European journal of pharmacology.

[8]  Gianluigi Lauro,et al.  Inverse virtual screening of antitumor targets: pilot study on a small database of natural bioactive compounds. , 2011, Journal of natural products.

[9]  D. Bojanic,et al.  Impact of high-throughput screening in biomedical research , 2011, Nature Reviews Drug Discovery.

[10]  Shen Qing,et al.  Evaluation of various inverse docking schemes in multiple targets identification. , 2010, Journal of molecular graphics & modelling.

[11]  Didier Rognan,et al.  Binding of Protein Kinase Inhibitors to Synapsin I Inferred from Pair-Wise Binding Site Similarity Measurements , 2010, PloS one.

[12]  David S. Goodsell,et al.  AutoDock4 and AutoDockTools4: Automated docking with selective receptor flexibility , 2009, J. Comput. Chem..

[13]  Philip E. Bourne,et al.  Drug Discovery Using Chemical Systems Biology: Repositioning the Safe Medicine Comtan to Treat Multi-Drug and Extensively Drug Resistant Tuberculosis , 2009, PLoS Comput. Biol..

[14]  R. D. Dyer,et al.  Nuclear factor-kappaB mediated inhibition of cytokine production by imidazoline scaffolds. , 2009, Journal of medicinal chemistry.

[15]  Rui Wang,et al.  Synthesis and biological activities of novel nonpeptide angiotensin II receptor antagonists based on benzimidazole derivatives bearing a heterocyclic ring. , 2008, Bioorganic & medicinal chemistry.

[16]  L. Meijer,et al.  Inverse in silico screening for identification of kinase inhibitor targets. , 2007, Chemistry & biology.

[17]  P. Leeson,et al.  The influence of drug-like concepts on decision-making in medicinal chemistry , 2007, Nature Reviews Drug Discovery.

[18]  S. Ekins,et al.  In silico pharmacology for drug discovery: methods for virtual ligand screening and profiling , 2007, British journal of pharmacology.

[19]  Didier Rognan,et al.  In silico-guided target identification of a scaffold-focused library: 1,3,5-triazepan-2,6-diones as novel phospholipase A2 inhibitors. , 2006, Journal of medicinal chemistry.

[20]  C. E. Peishoff,et al.  A critical assessment of docking programs and scoring functions. , 2006, Journal of medicinal chemistry.

[21]  M. Remko,et al.  Theoretical study of structure, pKa, lipophilicity, solubility, absorption, and polar surface area of some centrally acting antihypertensives. , 2006, Bioorganic & medicinal chemistry.

[22]  Duane D. Miller,et al.  Bioisosteric phentolamine analogs as potent α-adrenergic antagonists , 2005 .

[23]  B. Shoichet,et al.  Hierarchical docking of databases of multiple ligand conformations. , 2005, Current topics in medicinal chemistry.

[24]  M. Rarey,et al.  FlexX‐Scan: Fast, structure‐based virtual screening , 2004, Proteins.

[25]  B Li,et al.  Creating chemical diversity to target protein kinases. , 2004, Combinatorial chemistry & high throughput screening.

[26]  N. Paul,et al.  Recovering the true targets of specific ligands by virtual screening of the protein data bank , 2004, Proteins.

[27]  K. Andrews,et al.  Novel imidazoline compounds that inhibit Kir-mediated vasorelaxation in rat middle cerebral artery , 2003, Naunyn-Schmiedeberg's Archives of Pharmacology.

[28]  E. Koonin,et al.  The structure of the protein universe and genome evolution , 2002, Nature.

[29]  R. Glennon,et al.  Homoazanicotine: a structure-affinity study for nicotinic acetylcholine (nACh) receptor binding. , 2002, Journal of medicinal chemistry.

[30]  Herbert Waldmann,et al.  From protein domains to drug candidates-natural products as guiding principles in the design and synthesis of compound libraries. , 2002, Angewandte Chemie.

[31]  Tudor I. Oprea.  Current trends in lead discovery: Are we looking for the appropriate properties? , 2002, J. Comput. Aided Mol. Des..

[32]  Todd J. A. Ewing,et al.  DOCK 4.0: Search strategies for automated molecular docking of flexible molecule databases , 2001, J. Comput. Aided Mol. Des..

[33]  Y.Z. Chen,et al.  Ligand–protein inverse docking and its potential use in the computer search of protein targets of a small molecule , 2001, Proteins.

[34]  P. Jennings,et al.  Structural Characterization of Protein Kinase A as a Function of Nucleotide Binding , 2001, The Journal of Biological Chemistry.

[35]  I. Kuntz,et al.  Flexible ligand docking: A multistep strategy approach , 1999, Proteins.

[36]  D. E. Clark,et al.  Flexible docking using tabu search and an empirical estimate of binding affinity , 1998, Proteins.

[37]  Colin McMartin,et al.  QXP: Powerful, rapid computer algorithms for structure-based drug design , 1997, J. Comput. Aided Mol. Des..

[38]  P Willett,et al.  Development and validation of a genetic algorithm for flexible docking. , 1997, Journal of molecular biology.

[39]  Jurgen Sygusch,et al.  High resolution fast quantitative docking using fourier domain correlation techniques , 1997, Proteins.

[40]  A. N. Jain,et al.  Hammerhead: fast, fully automated docking of flexible ligands to protein binding sites. , 1996, Chemistry & biology.

[41]  S. Buchwald,et al.  A Simple Catalytic Method for the Conversion of Aryl Bromides to Arylamines , 1995 .

[42]  J. Hartwig,et al.  Palladium-catalyzed synthesis of arylamines from aryl halides. Mechanistic studies lead to coupling in the absence of tin reagents , 1995 .

[43]  Gennady M Verkhivker,et al.  Molecular recognition of the inhibitor AG-1343 by HIV-1 protease: conformationally flexible docking by evolutionary programming. , 1995, Chemistry & biology.

[44]  T. Hunter,et al.  The eukaryotic protein kinase superfamily: kinase (catalytic) domain structure and classification 1 , 1995, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[45]  J. Scott Dixon,et al.  Flexible ligand docking using a genetic algorithm , 1995, J. Comput. Aided Mol. Des..

[46]  M Karplus,et al.  HOOK: A program for finding novel molecular architectures that satisfy the chemical and steric requirements of a macromolecule binding site , 1994, Proteins.

[47]  Robert P. Sheridan,et al.  FLOG: A system to select ‘quasi-flexible’ ligands complementary to a receptor of known three-dimensional structure , 1994, J. Comput. Aided Mol. Des..

[48]  Hans-Joachim Böhm,et al.  The computer program LUDI: A new method for the de novo design of enzyme inhibitors , 1992, J. Comput. Aided Mol. Des..

[49]  B. E. Evans,et al.  Methods for drug discovery: development of potent, selective, orally effective cholecystokinin antagonists. , 1988, Journal of medicinal chemistry.

[50]  T. Hunter,et al.  The protein kinase family: conserved features and deduced phylogeny of the catalytic domains. , 1988, Science.

[51]  J M Blaney,et al.  A geometric approach to macromolecule-ligand interactions. , 1982, Journal of molecular biology.

[52]  A. Hofmann,et al.  Serine/threonine phosphatases in socioeconomically important parasitic nematodes--prospects as novel drug targets? , 2011, Biotechnology advances.

[53]  N. Gray,et al.  Targeting cancer with small molecule kinase inhibitors , 2009, Nature Reviews Cancer.

[54]  Ronald J Quinn,et al.  A common protein fold topology shared by flavonoid biosynthetic enzymes and therapeutic targets. , 2006, Journal of natural products.

[55]  Duane D. Miller,et al.  Bioisosteric phentolamine analogs as potent alpha-adrenergic antagonists. , 2005, Bioorganic & medicinal chemistry letters.

[56]  Tudor I. Oprea,et al.  Current trends in lead discovery: Are we looking for the appropriate properties? , 2004, Molecular Diversity.

[57]  Herbert Waldmann,et al.  From protein domains to drug candidates – natural products as guiding principles in , 2002 .